Impact of Recent Findings on Study Design of Future Autism Clinical Trials

Eric Hollander; Ann Phillips; Bryan H. King; Donald Guthrie; Michael G. Aman; Paul Law; Thomas Owley; Ricki Robinson

doi:10.1017/S109285290000835X

Impact of Recent Findings on Study Design of Future Autism Clinical Trials

Eric Hollander, Ann Phillips, Bryan H. King, Donald Guthrie, Michael G. Aman, Paul Law, Thomas Owley, Ricki Robinson

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

There are specific challenges to studying the design of pharmacologic trials in child/adolescent and adult autism, such as subject stratification and parallel versus crossover designs. This article describes how optimal study design is influenced by subject selection and outcome measures chosen. Lessons learned in study design from the Research Units on Pediatric Psychopharmacology Autism Network trial with risperidone, Seaver Center trials with fluoxetine and valproate, Dartmouth trials with amantadine, and National Institutes of Health secretin trials are highlighted. The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described.

Original language	English (US)
Pages (from-to)	49-56
Number of pages	8
Journal	CNS spectrums
Volume	9
Issue number	1
DOIs	https://doi.org/10.1017/S109285290000835X
State	Published - Jan 2004
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S109285290000835X

Cite this

@article{c0f9db82d6224ad083f77d5c14b1cdca,

title = "Impact of Recent Findings on Study Design of Future Autism Clinical Trials",

abstract = "There are specific challenges to studying the design of pharmacologic trials in child/adolescent and adult autism, such as subject stratification and parallel versus crossover designs. This article describes how optimal study design is influenced by subject selection and outcome measures chosen. Lessons learned in study design from the Research Units on Pediatric Psychopharmacology Autism Network trial with risperidone, Seaver Center trials with fluoxetine and valproate, Dartmouth trials with amantadine, and National Institutes of Health secretin trials are highlighted. The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described.",

author = "Eric Hollander and Ann Phillips and King, {Bryan H.} and Donald Guthrie and Aman, {Michael G.} and Paul Law and Thomas Owley and Ricki Robinson",

year = "2004",

month = jan,

doi = "10.1017/S109285290000835X",

language = "English (US)",

volume = "9",

pages = "49--56",

journal = "CNS spectrums",

issn = "1092-8529",

publisher = "MBL Communications",

number = "1",

}

TY - JOUR

T1 - Impact of Recent Findings on Study Design of Future Autism Clinical Trials

AU - Hollander, Eric

AU - Phillips, Ann

AU - King, Bryan H.

AU - Guthrie, Donald

AU - Aman, Michael G.

AU - Law, Paul

AU - Owley, Thomas

AU - Robinson, Ricki

PY - 2004/1

Y1 - 2004/1

N2 - There are specific challenges to studying the design of pharmacologic trials in child/adolescent and adult autism, such as subject stratification and parallel versus crossover designs. This article describes how optimal study design is influenced by subject selection and outcome measures chosen. Lessons learned in study design from the Research Units on Pediatric Psychopharmacology Autism Network trial with risperidone, Seaver Center trials with fluoxetine and valproate, Dartmouth trials with amantadine, and National Institutes of Health secretin trials are highlighted. The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described.

AB - There are specific challenges to studying the design of pharmacologic trials in child/adolescent and adult autism, such as subject stratification and parallel versus crossover designs. This article describes how optimal study design is influenced by subject selection and outcome measures chosen. Lessons learned in study design from the Research Units on Pediatric Psychopharmacology Autism Network trial with risperidone, Seaver Center trials with fluoxetine and valproate, Dartmouth trials with amantadine, and National Institutes of Health secretin trials are highlighted. The Internet System for Assessing Autistic Children system for managing multicenter clinical trials in autism and statistical issues in autism research are also described.

UR - http://www.scopus.com/inward/record.url?scp=1842505964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842505964&partnerID=8YFLogxK

U2 - 10.1017/S109285290000835X

DO - 10.1017/S109285290000835X

M3 - Review article

C2 - 14999175

AN - SCOPUS:1842505964

SN - 1092-8529

VL - 9

SP - 49

EP - 56

JO - CNS spectrums

JF - CNS spectrums

IS - 1

ER -

Impact of Recent Findings on Study Design of Future Autism Clinical Trials

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this